Mobic and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with Mobic (meloxicam).
Alcohol (Ethanol) Meloxicam
Moderate Drug Interaction
GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.
MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.
References (1)
- (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
Switch to consumer interaction data
Meloxicam High Blood Pressure (Hypertension)
Major Potential Hazard, Moderate plausibility
NSAIDs - fluid retention
Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations. NSAIDs (including topicals) can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. NSAIDs should be used with caution in patients with preexisting fluid retention, hypertension, or history of heart failure. NSAIDs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure; if an NSAID is used in such patients, they should be monitored for signs of worsening heart failure. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
References (19)
- (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
- (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
- (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
- (2002) "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories
- (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
- (2006) "Product Information. Anaprox (naproxen)." Roche Laboratories
- (2001) "Product Information. Clinoril (sulindac)." Merck & Co., Inc
- (2001) "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical
- (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
- (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
- (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
- (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
- (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Daypro (oxaprozin)." Searle
- (2001) "Product Information. Celebrex (celecoxib)." Searle
- (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
- (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
- (2016) "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)
- (2022) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals Group, SUPPL-52
Switch to consumer interaction data
Mobic drug interactions
There are 464 drug interactions with Mobic (meloxicam).
Mobic disease interactions
There are 10 disease interactions with Mobic (meloxicam) which include:
- asthma
- fluid retention
- GI toxicity
- rash
- renal toxicities
- thrombosis
- anemia
- hepatotoxicity
- hyperkalemia
- platelet aggregation inhibition
More about Mobic (meloxicam)
- Mobic consumer information
- Check interactions
- Compare alternatives
- Reviews (131)
- Drug images
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- Support group
- Drug class: Nonsteroidal anti-inflammatory drugs
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.